Intra-Cellular Therapies Net Tangible Assets

As of the most recent data (December 2024), ITCI shows a net tangible assets of $1.1B. That compares with $590M in the prior-year period — up 94.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's net tangible assets is now $1.1B (was $590M) — a 94.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

Tracking ITCI's net tangible assets over time shows whether Intra-Cellular Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $1.1B That compares with $590M in the prior-year period — up 94.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $1.1B) with ownership activity and broader fundamentals.

Intra-Cellular Therapies's net tangible assets is $1.1B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.